The Patent Trial and Appeal Board has instituted four of the Coalition for Affordable Drugs’ IPR petitions challenging Celgene patents, bringing the total number its petitions instituted to seven and greatly shifting the success rate of what one law firm calls the “PTAB Crashers”
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Michael Gaertner explains why Locke Lord’s merger with Troutman Pepper sparked the need to seek a new home and why Buchanan Ingersoll & Rooney ticked the right boxes
Emily O’Neill, BAT's new head of patents, considers why the first 90 days in a new role are crucial for establishing credibility and understanding your organisation’s culture and objectives